Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia

Park, Sun Gu; Yeo, Jeong Kyun; Cho, Dae Yeon; Park, Min Gu

doi:10.1080/13685538.2017.1311857

Cited by 34 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wang et al [64] found that Asian patients with MetS had a higher PSA level than non-MetS patients. However, according to others, the PSA level was similar in both groups [23,[30][31][32]34]. Our study suggested that no significant difference in PSA level between patients with and without MetS.…”

Section: Discussionsupporting

confidence: 75%

“…In the final statistical analysis, there were 18 studies reported the PSA level [16,17,19,20,[22][23][24][25][26][27][28][30][31][32][33][34][35][36]. There was no statistical difference in PSA level between the presence of MetS and the absence of MetS (WMD ¼ 0.04; 95% Cl: À0.06 to 0.13; p ¼ .43; Figure 3).…”

Section: Prostate-specific Antigenmentioning

confidence: 99%

“…The QoL was reported in ten studies including 10,073 patients [17,19,20,[23][24][25][26][32][33][34]. Analysis of these studies showed that there was no statistical significance in QoL between patients with and without MetS (WMD ¼ À0.01; 95% Cl: À0.08 to 0.05; p ¼ .70; Figure 4(c)).…”

Section: Quality Of Lifementioning

confidence: 99%

See 2 more Smart Citations

The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis

Peng

Cao

et al. 2020

The Aging Male

View full text Add to dashboard Cite

Objective: We performed this meta-analysis to assess the association between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH). Method: We conducted extensive searches on the PubMed, Science and Cochrane Library to identify all articles. Outcomes including annual prostate growth rate, prostate volume (PV), International Prostate Symptom Score (IPSS), IPSS sub-scores (voiding and storage), prostatespecific antigen (PSA), maximum urine flow rate (Qmax), post-void residual urine volume (PVR) and quality of life (QoL) were assessed. Results: 21 studies with 15,317 patients were included. Patients with MetS had higher annual prostate growth rate [weighted mean difference (WMD) ¼ 0.79; p < .001], larger PV (WMD ¼ 2.62; p < .001), lower Qmax (WMD ¼ À0.48; p ¼ .001) and more PVR (WMD ¼ 8.28; p < .001). However, no significant differences were found between two groups in IPSS (WMD ¼ 0.20; p ¼ .37), IPSS-voiding (WMD ¼ À0.05; p ¼ .78), IPSS-storage (WMD ¼ À0.22; p ¼ .26), PSA (WMD ¼ 0.04; p ¼ .43), and QoL (WMD ¼ À0.01; p ¼ .70). Conclusions:The study suggested that MetS may be one of the risk factors for the clinical progress of BPH. However, further study is warranted to support these results.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Prostate-specific Antigenmentioning

confidence: 99%

See 1 more Smart Citation

The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis

Peng

Cao

et al. 2020

The Aging Male

View full text Add to dashboard Cite

show abstract

“…On the other hand, clinical studies have been conducted to evaluate the effect of metabolic syndrome on the relationship between vitamin D level and lower urinary tract symptoms. Park et al evaluated the effect of metabolic syndrome on the relationship between vitamin D level and lower urinary tract symptoms and found that vitamin D level positively correlated with total testosterone level in patients without metabolic syndrome and negatively correlated with IPSS and prostate volume (21). In the study conducted by Caretta et al, the relation between vitamin D deficiency and lower urinary tract symptoms in type 2 diabetes mellitus (DM) patients was evaluated and it was observed that 25 OH vitamin D levels decreased progressively with increasing IPSS scores in type 2 DM patients.…”

Section: Discussionmentioning

confidence: 99%

Yaşlanan erkekte benign prostat hiperplazisine bağlı alt üriner sistem semptomları ile vitamin D seviyesi arasındaki ilişki.

Kutluhan¹,

Toprak²

2020

Yeni Üroloji Dergisi

View full text Add to dashboard Cite

Özet Amaç: 40 yaşın üzerindeki erkeklerde vitamin D düzeyleri ile benign prostat hiperplazisi (BPH) ne bağlı alt üriner sistem semptomları (AÜSS) arasındaki ilişkiyi belirlemeyi amaçladık. Gereç Ve Yöntemler: Çalışmamıza Ocak 2019-Nisan 2019 tarihleri arasında kliniğimize BPH'ya bağlı AÜSS ile başvuran 48 hasta (BPH grubu) ile AÜSS olmayan ve rutin ürolojik kontrole gelen 52 hasta (Kontrol grubu) dahil edildi. Her iki grubun vitamin D, total PSA, total testosteron değerleri, IPSS skorları, prostat hacimleri ve üroflowmetrideki maksimum idrar hızı (Qmax) değerlendirildi. Bulgular: BPH grubundaki 48 hastanın yaş ortalaması 65,37 ± 7,24, kontrol grubundaki 52 hastanın yaş ortalaması 64,09 ± 8,22 idi. BPH ve kontrol grupları arasında 25 hidroksi vitamin D değerlerinin ortalama değerleri açısından istatistiksel olarak anlamlı bir fark vardı (p <0.001). BPH grubundaki hastalar alt gruplarına göre incelendiğinde; Orta AÜSS (33 hasta) ve şiddetli AÜSS (15 hasta) grubu arasında 25 hidroksi vitamin D düzeyi açısından istatistiksel olarak anlamlı fark yoktu (p> 0.05). Sonuç: Çalışmamız BPH ve AÜSS olan hastalarda 25 hidroksi vitamin-D düzeylerinin şikayeti olmayan benzer yaş grubundakilerden düşük olduğunu göstermiştir. Buna dayanarak, vitamin D düzeylerinde artış olan hastaların semptomlarında bir iyileşme olabileceği düşünülmektedir. Bu konuda kesin bir karara varmak için, daha fazla sayıda randomize kontrollü prospektif çalışmaya ihtiyaç vardır.

show abstract

“…Vitamin D is an essential, fat-soluble vitamin in human body, which is closely related to cell proliferation, differentiation, infection and immune system [ 7 ]. Uric acid is a marker of metabolic disorders and is associated with stroke, peripheral artery disease, and CHD[ 8 ].…”

Section: Introductionmentioning

confidence: 99%

The application value of serum 25(OH)D3, uric acid, triglyceride, and homeostasis model assessment of insulin resistance in male patients with hyperuricemia combined with hypogonadism

et al. 2021

View full text Add to dashboard Cite

Background The purpose of this study was to investigate the application value of serum 25(OH)D3, uric acid, triglyceride (TG), and homeostasis model assessment of insulin resistance (HOMA-IR) in male patients with hyperuricemia combined with hypogonadism. Methods From August 2018 to August 2020, a total of 198 male patients with primary hyperuricemia were prospectively enrolled in our hospital for inpatient treatment in the department of Metabolism and Endocrinology. They are divided into normal gonadal function group (normal group, n = 117) and hypogonadal function group (hypogonadism group, n = 81), according to free testosterone (FT) level, International Index of Erectile Function (IIEF-5), and androgen deficiency in the aging male (ADAM) questionnaires. Laboratory indexes were compared between two groups. Multivariate logistic regression was applied to analyze the influencing factors of hypogonadism. Results Among the 198 hyperuricemia patients, 40.91 % were hypogonadism. Compared with the normal group, the BMI, waist circumference (WC), and the prevalence of non-alcoholic fatty liver disease (NAFLD), hyperlipidemia (HLP), and obesity (OB) in the hypogonadism group were higher, and the difference was statistically significant (P < 0.05, respectively). The levels of fasting plasma glucose (FPG), fasting insulin (FINS), homeostasis model assessment of insulin resistance (HOMA-IR), triacylglycerol (TG), serum uric acid (SUA), alanine transaminase (ALT) of hypogonadism group were higher than those of normal group, while the levels of TT, FT, E2, 25(OH)D3 of hypogonadism group were lower than those of normal group (P < 0.05, respectively). Pearson’s linear correlation was used to analyze the correlation between the indicators with significant differences in general data and laboratory indicators and hypogonadism. BMI, WC, HOMA-IR, TG, SUA, TT, FT, 25(OH)D3, E2 were positively correlated with hypogonadism (r = 0.556, 0.139, 0.473, 0.143, 0.134, 0.462, 0.419, 0.572, 0.601, P = 0.012, 0.027, 0.018, 0.019, 0.028, 0.029, 0.030, 0.009, 0.003, respectively). Taking the above indicators as independent variables and hypogonadism as the dependent variable, logistic regression analysis found that the risk factors for hypogonadism were SUA, WC, BMI, HOMA-IR, TG, TT, FT, E2, and 25(OH) D3. Conclusions Serum 25(OH)D3, SUA, HOMA-IR, TG levels were positively correlated with male hyperuricemia patients with hypogonadism. They have important application value in the diagnosis of male hyperuricemia patients with hypogonadism.

show abstract

Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia

Abstract: The clinical usefulness of vitamin D for treatment of hypogonadism or LUTS/BPH varies according to metabolic status.

Cited by 34 publications

References 25 publications

The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis

The association between metabolic syndrome and benign prostatic hyperplasia: a systematic review and meta-analysis

Yaşlanan erkekte benign prostat hiperplazisine bağlı alt üriner sistem semptomları ile vitamin D seviyesi arasındaki ilişki.

The application value of serum 25(OH)D3, uric acid, triglyceride, and homeostasis model assessment of insulin resistance in male patients with hyperuricemia combined with hypogonadism

Contact Info

Product

Resources

About